{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:02:35Z","timestamp":1784649755980,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017607","name":"Shenzhen Basic Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xcrm.2026.102885","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:39:18Z","timestamp":1782398358000},"page":"102885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors"],"prefix":"10.1016","volume":"7","author":[{"given":"Xuechun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexiu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingen","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunfu","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-7757","authenticated-orcid":false,"given":"Yu J.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102885_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41416-024-02684-w","article-title":"The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications","volume":"131","author":"Chen","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.xcrm.2026.102885_bib4","article-title":"Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer","volume":"391\u2013392","author":"Wang","year":"2023","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.xcrm.2026.102885_bib5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/febs.15523","article-title":"Driving CARs with alternative navigation tools - the potential of engineered binding scaffolds","volume":"288","author":"Zajc","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.xcrm.2026.102885_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells11010021","article-title":"Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing","volume":"11","author":"Branella","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2026.102885_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12967-024-05197-5","article-title":"Deciphering the importance of culture pH on CD22 CAR T-cells characteristics","volume":"22","author":"Prochazkova","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102885_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102885_bib9","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1038\/s41467-023-40303-z","article-title":"Complementarity-determining region clustering may cause CAR-T cell dysfunction","volume":"14","author":"Sar\u00e9n","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102885_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2195517","article-title":"\u201cStapling\u201d scFv for multispecific biotherapeutics of superior properties","volume":"15","author":"Boucher","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2026.102885_bib11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2021.11.004","article-title":"DNA nanotechnology-facilitated ligand manipulation for targeted therapeutics and diagnostics","volume":"340","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xcrm.2026.102885_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nucmedbio.2013.09.005","article-title":"(6)(8)Ga-NODAGA-VEGF(1)(2)(1) for in vivo imaging of VEGF receptor expression","volume":"41","author":"Kang","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.xcrm.2026.102885_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/mp100446t","article-title":"Multiplexed PET probes for imaging breast cancer early response to VEGF(1)(2)(1)\/rGel treatment","volume":"8","author":"Yang","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.xcrm.2026.102885_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/biomedicines5030042","article-title":"Targeting of Tumor Neovasculature with GrB\/VEGF, a Novel Cytotoxic Fusion Protein","volume":"5","author":"Mohamedali","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.xcrm.2026.102885_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102885_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01467-9","article-title":"GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer","volume":"16","author":"Fan","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102885_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcyt.2021.05.008","article-title":"Anti-tumor effects of vascular endothelial growth factor\/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells","volume":"23","author":"Xing","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.xcrm.2026.102885_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib19","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102885_bib20","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1002\/anie.201601902","article-title":"Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer","volume":"55","author":"Cao","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.xcrm.2026.102885_bib21","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","article-title":"ROR1-targeting switchable CAR-T cells for cancer therapy","volume":"41","author":"Peng","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2026.102885_bib22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/gutjnl-2018-316595","article-title":"Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma","volume":"68","author":"Raj","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2026.102885_bib23","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102885_bib24","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00262-023-03437-z","article-title":"Switchable CAR T cell strategy against osteosarcoma","volume":"72","author":"Hidalgo","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102885_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","article-title":"Engineering switchable and programmable universal CARs for CAR T therapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102885_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2026.102885_bib27","doi-asserted-by":"crossref","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102885_bib28","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.3390\/ijms26115024","article-title":"CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells","volume":"26","author":"von Jutrzenka-Trzebiatowski","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102885_bib29","doi-asserted-by":"crossref","first-page":"9751","DOI":"10.1038\/s41467-024-54150-z","article-title":"Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102885_bib30","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/acssynbio.1c00007","article-title":"Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers","volume":"10","author":"Cao","year":"2021","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.xcrm.2026.102885_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/cgt.2016.12","article-title":"VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans","volume":"23","author":"Kazemi","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102885_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2018.09.005","article-title":"Light-enhanced VEGF\/rGel: A tumor targeted modality with vascular and immune-mediated efficacy","volume":"288","author":"Weyergang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xcrm.2026.102885_bib33","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1593\/neo.05292","article-title":"The vascular-targeting fusion toxin VEGF121\/rGel inhibits the growth of orthotopic human bladder carcinoma tumors","volume":"7","author":"Mohamedali","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.xcrm.2026.102885_bib34","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1158\/1535-7163.MCT-13-0165","article-title":"The functionalized human serine protease granzyme B\/VEGF(1)(2)(1) targets tumor vasculature and ablates tumor growth","volume":"12","author":"Mohamedali","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.102885_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102885_bib37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.csbj.2020.05.006","article-title":"Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies","volume":"18","author":"Dickopf","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.xcrm.2026.102885_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/procel\/pwae034","article-title":"A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies","volume":"16","author":"Zhao","year":"2024","journal-title":"Protein Cell"},{"key":"10.1016\/j.xcrm.2026.102885_bib39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/ni.3259","article-title":"TCR-induced sumoylation of the kinase PKC-\u03b8 controls T cell synapse organization and T cell activation","volume":"16","author":"Wang","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102885_bib40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.phrs.2007.04.009","article-title":"Protein kinase C theta (PKC\u03b8):: A key player in T cell life and death","volume":"55","author":"Hayashi","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.xcrm.2026.102885_bib41","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.178.7.4650","article-title":"T cell activation by antibody-like immunoreceptors: The position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells","volume":"178","author":"Hombach","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102885_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2026.102885_bib43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102885_bib44","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2026.102885_bib45","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1038\/s41467-024-52951-w","article-title":"Unmasking AlphaFold to integrate experiments and predictions in multimeric complexes","volume":"15","author":"Mirabello","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102885_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-017-0437-8","article-title":"Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells","volume":"10","author":"Qin","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102885_bib47","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to Address Chimeric Antigen Receptor Tonic Signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.102885_bib48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.xcrm.2026.102885_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2026.102885_bib50","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angiogenesis","volume":"146","author":"Potente","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102885_bib51","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102885_bib53","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s11033-020-05306-9","article-title":"Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer","volume":"47","author":"Farzaneh Behelgardi","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.xcrm.2026.102885_bib54","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nprot.2010.6","article-title":"In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract","volume":"5","author":"Arnaoutova","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102885_bib55","first-page":"1843","article-title":"Signature of the vascular tumor microenvironment as a marker of the therapeutic response to doxorubicin in a model of osteosarcoma","volume":"12","author":"Crenn","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102885_bib56","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/j.bbagen.2018.08.013","article-title":"Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K\/AKT and MAPK\/ERK1\/2 pathway","volume":"1862","author":"Sadremomtaz","year":"2018","journal-title":"Bba-Gen Subjects"},{"key":"10.1016\/j.xcrm.2026.102885_bib57","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00259-007-0524-0","article-title":"A new PET tracer specific for vascular endothelial growth factor receptor 2","volume":"34","author":"Wang","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.xcrm.2026.102885_bib58","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/2326-6066.CIR-19-0360","article-title":"Anti-VEGF Treatment Enhances CD8 T-cell Antitumor Activity by Amplifying Hypoxia","volume":"8","author":"de Almeida","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102885_bib59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102885_bib60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-3-319-67577-0_13","article-title":"Immunotherapeutic Targeting of Tumor-Associated Blood Vessels","volume":"1036","author":"Fabian","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.xcrm.2026.102885_bib61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","article-title":"Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma","volume":"2","author":"Ma","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib62","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00228-021-03179-w","article-title":"Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer","volume":"77","author":"Petitcollin","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102885_bib63","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.7150\/thno.75037","article-title":"A Novel Her2\/VEGFR2\/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2026.102885_bib64","doi-asserted-by":"crossref","first-page":"e002151","DOI":"10.1136\/jitc-2020-002151","article-title":"VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding","volume":"9","author":"Lanitis","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib65","doi-asserted-by":"crossref","first-page":"e005583","DOI":"10.1136\/jitc-2022-005583","article-title":"Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice","volume":"11","author":"Dong","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib66","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01487-5","article-title":"Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy","volume":"16","author":"Niu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102885_bib67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1054\/bjoc.2000.1279","article-title":"The 121 amino acid isoform of vascular endothelial growth factor is move strongly tumorigenic than other splice variants in vivo","volume":"83","author":"Zhang","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102885_bib68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102885_bib69","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1084\/jem.160.4.1126","article-title":"Low and High-Affinity Cellular Receptors for Interleukin-2 - Implications for the Level of Tac Antigen","volume":"160","author":"Robb","year":"1984","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102885_bib70","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2147\/ITT.S494670","article-title":"Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors","volume":"13","author":"Zhou","year":"2024","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.xcrm.2026.102885_bib71","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/ijms22020843","article-title":"The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature","volume":"22","author":"Korbecki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102885_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-06770-w","article-title":"CD28 hinge used in chimeric antigen receptor (CAR) T-cells exhibits local structure and conformational exchange amidst global disorder","volume":"7","author":"Folimonova","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2026.102885_bib73","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/protein\/6.8.989","article-title":"An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability","volume":"6","author":"Whitlow","year":"1993","journal-title":"Protein Eng."},{"key":"10.1016\/j.xcrm.2026.102885_bib74","doi-asserted-by":"crossref","DOI":"10.1186\/s12934-015-0202-z","article-title":"Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems","volume":"14","author":"Della Cristina","year":"2015","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.xcrm.2026.102885_bib75","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13287-024-03871-5","article-title":"Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34(+) cells and PD-L1 CAR-modified UCB-CD34(+)-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells","volume":"15","author":"Ghaedrahmati","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.xcrm.2026.102885_bib76","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102885_bib77","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.str.2016.12.012","article-title":"Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A","volume":"25","author":"Markovic-Mueller","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.xcrm.2026.102885_bib78","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2011-11-390922","article-title":"Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization","volume":"119","author":"Brozzo","year":"2012","journal-title":"Blood"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:06:28Z","timestamp":1784646388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666379126003022"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102885","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102885"}}